Immunic to participate in investor and scientific conferences in march

New york , march 7, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in march: march 11-13: leerink partners global biopharma conference . daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking